ADVERTISEMENT

Prostate cancer: conventional and stereotactic body radiotherapy show similar 2-year toxicity

Deepa Koli   |   Clinical Summary   |   23 September 2022
ADVERTISEMENT

Takeaway

  • There is no difference in the 2-year Radiation Therapy Oncology Group (RTOG) toxicity rates with five fraction s tereotactic body radiotherapy (SBRT) and conventional schedules of radiotherapy in patients with low- to intermediate-risk prostate cancer.

Why this matters

  • Prostate SBRT was found to be safe and associated with low...

          

January Challenge

Ends in 2d 15h
left
right

Topic Challenges

left
right